Tradestie Institutional Equity Comparison Engine

IOVA vs XOMA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XOMA Overall Edge

XOMA Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to XOMA Royalty Corporation Common Stock (XOMA) driven by superior Valuation, Growth & Margin while IOVA counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, IOVA trades at N/M Forward P/E with -60.8% operating margin (+80.1% YoY revenue) versus XOMA at 21.5x Forward P/E and -3.9% operating margin (-22.6% YoY). In options structure, IOVA sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner XOMA
IOVA N/M vs XOMA 21.5x Fwd P/E
Growth & Margin Winner XOMA
Op Margin -60.8% vs -3.9% ยท YoY +80.1% vs -22.6%
Momentum & Technical Winner IOVA
1Y +213.5% vs +44.0% ยท 52W Pos 41% vs 78%
Options & Structure Winner IOVA
BREAKDOWN (25th %ile IV) vs UNCLASSIFIED (100th %ile IV)
IOVA NASDAQ
Iovance Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.55
-2.64% 1D
Market Cap $3.5B
1M Return -44.53%
1Y Return +213.49%
Forward P/E N/M
Unified AI Score
67.5 / 100 BUY
Tech 68.0 Fund 73.0 Flow 70.0 Mom 70.0
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
1M Return -3.81%
1Y Return +43.98%
Forward P/E 21.5x
Unified AI Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IOVA +213.49% XOMA +43.98% Spread: +43.03 pp (IOVA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IOVA TTM Op. Margin: -60.8% XOMA TTM Op. Margin: -3.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IOVA vs XOMA. Trailing 12-month operating profitability (IOVA -60.8% vs XOMA -3.9%) and valuation multiples (IOVA N/M vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IOVA (3) vs XOMA (7)
Institutional Metric IOVA XOMA Criterion Row Winner
Market Capitalization Scale $3.5B $781.8M Larger Scale IOVA
Trailing P/E Ratio Valuation N/M 28.2x Lower Multiple XOMA
Forward P/E Ratio Valuation N/M 21.5x Lower Multiple XOMA
Revenue Growth (YoY) Growth +80.1% -22.6% Higher Growth IOVA
Operating Margin (TTM) Profitability -60.8% -3.9% Higher Margin XOMA
Net Profit Margin Profitability -58.2% 69.6% Higher Margin XOMA
Return on Equity (ROE) Capital Efficiency -29.1% 34.2% Higher ROE XOMA
52-Week Range Position Momentum 41% ($2โ€“$15) 78% ($22โ€“$45) Stronger Trend XOMA
Beta / 30D Volatility Risk Regime 1.58ฮฒ ยท 144% Vol 0.68ฮฒ ยท 37% Vol Lower Realized Risk XOMA
Unified Institutional Score Composite Signal 67.5 / 100 (BUY) 55.8 / 100 (HOLD) Higher Composite IOVA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IOVA vs XOMA Buy Guide
IOVA BREAKDOWN
33d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Compressed (<25th %ile)
Live IOVA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live XOMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IOVA nor XOMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.